Excedrin migraine medications are some of the most commonly used drugs to treat migraine headaches.
However, people who suffer from the intense, painful headaches may have to try new treatments for a bit.
Manufacturer GlaxoSmithKline (GSK) has temporarily halted production of Excedrin Migraine and Excedrin Extra Strength, according to multiple reports.
The company confirmed to Healthline that it is “experiencing a temporary supply issue” that affects the caplet and geltab forms of the two products.
“We apologize for any inconvenience this stock issue may cause to consumers. Please be assured we are working hard to resolve the issue so we can restore supply as quickly as possible,” a GSK spokesperson said.
It isn’t clear how extensive or long lasting the supply issue will be, but it underlines the importance of these over-the-counter medications to people who get migraine headaches — and, perhaps, the danger in relying too heavily on one particular medication.
Experts say a potential temporary shortage might have a silver lining since using a particular medication too frequently can lead to an increase in headaches.
If Excedrin supplies do run out at your local store, there are other treatment options that can be discussed with a healthcare provider.
“All three of the ingredients in these medications are available separately, and there are times when a doctor may actually recommend one or two of the ingredients but not all three,” Dr. Thomas Berk, who specializes in headaches at NYU Langone Health in New York, told Healthline.
Excedrin Migraine contains the pain reliever acetaminophen, the anti-inflammatory aspirin, and caffeine.
“There are many over-the-counter and prescription medications used for migraine and other headaches that your doctor may recommend as well,” Berk said.
He noted that some, such as triptans, which affect chemicals in the brain, generally require a prescription. But there are other options for treating migraine out there.
In January 2020, the drug manufacturer GlaxoSmithKline stopped production of its 2 products, including Excedrin, as a precaution due to inconsistent weighting of ingredients used in Excedrin. However, GSK resumed production and now you should be seeing the product back on shelves.